Mometasone furoate 0.1%
Cream / Ointment · Topical · Pediatric
A once-daily mid-potency steroid, the dosing simplicity matters in pediatric eczema management, where twice-daily regimens are harder to maintain consistently and adherence directly determines outcome.
Available nowIncluded in your child’s plan if prescribed · Rx required
You won’t be charged until a clinician reviews and approves your child’s case.
Start your child’s assessment →Not sure this is right? Take the quiz →
Why is Mometasone furoate 0.1% included?
Adherence is the most underappreciated variable in pediatric eczema outcomes. Twice-daily topical steroid regimens are objectively harder to maintain for children (applying medication at school, during active days, over the protests of a child who finds it uncomfortable) than once-daily regimens. Mometasone furoate 0.1% is one of the few mid-potency steroids with strong evidence supporting once-daily efficacy, making it a practical choice when the clinical goal is sustained treatment adherence over a full course.
Mometasone is FDA-approved for atopic dermatitis in children aged 2 and older. It sits at the stronger end of the mid-potency range, some classification systems place it as Class IV (mid-high) rather than Class V (mid). This gives it a clinical edge for more established, moderately severe body flares in children where triamcinolone or fluticasone might require twice-daily use and mometasone can achieve equivalent clearance with once-daily application.
The availability of both cream and ointment in one Rx allows prescribing based on the child's specific presentation, cream for acute, weeping flares; ointment for dry, thickened, or lichenified patches that need better penetration.
How does it work?
Mometasone has a high affinity for the glucocorticoid receptor and a skin residence time of approximately 24 hours after a single application. This pharmacokinetic profile, sustained drug-receptor interaction following a single application, is what supports once-daily efficacy. After it's applied and absorbed, therapeutic concentrations in the skin remain above the level needed for anti-inflammatory activity for a full day, unlike some other mid-potency agents where receptor-active concentrations fall before 24 hours have passed.
The ointment formulation is more occlusive, which increases penetration and effective potency per application, useful for thickened plaques but requiring more caution about application amount and avoidance of occlusive dressings.
How strong is the evidence?
Mometasone 0.1% has pediatric-specific RCT data confirming once-daily efficacy for atopic dermatitis in children. Head-to-head pediatric trials comparing once-daily mometasone to twice-daily mid-potency alternatives show non-inferiority for clearance rates, the same outcome with half the applications. It appears in pediatric eczema guidelines as an established option, and the once-daily dosing recommendation has been specifically studied and confirmed in children, not extrapolated from adult data.
What are the limitations and risks?
Mometasone's position toward the stronger end of the mid-potency class means the standard mid-potency cautions apply with slightly more weight: not for the face, not for skin folds, not for extended uninterrupted daily use. In young children (under 5), the HPA axis suppression risk with large-area coverage requires careful attention to application amount and body surface area covered.
The ointment formulation can cause folliculitis (small inflamed bumps around hair follicles) in some patients, particularly on hair-bearing areas of the arms and legs. If this occurs, switch to cream and flag it to your clinician.
Once-daily dosing is an advantage for adherence, but for the same reason, parents should not assume that "just once" means they can apply liberally over large areas. Thin layer, appropriate areas, prescribed frequency, the rules are the same as for twice-daily steroids.
Frequently Asked Questions
Yes: the clinical trials confirm it. Mometasone's receptor affinity and skin retention time mean that a once-daily application maintains therapeutic concentrations for approximately 24 hours. Adding a second application doesn't increase efficacy and does increase cumulative dose. For children specifically, once-daily dosing is a real practical advantage and not a compromise.
Yes. For most acute pediatric presentations, the cream is entirely appropriate and more comfortable for children. The ointment has an advantage for dry, thickened, scaling chronic patches where better occlusion and penetration help, if your child's presentation is more often acutely inflamed and weeping rather than thick and scaling, the cream is the right vehicle.
Yes. The twice-weekly proactive maintenance approach that has evidence for fluticasone and triamcinolone has also been studied with mometasone in children. For children with recurring body-site eczema, twice-weekly maintenance on historically affected areas reduces flare frequency. Discuss with your clinician whether an acute course or a maintenance plan is the right approach for your child's pattern.
Extended daily use for a month without reassessment is not the recommended approach for any mid-potency steroid in children. 7–14 day acute courses are the standard, followed by stopping once the flare clears. If your child's eczema is severe enough that body-site involvement is continuous, the discussion shifts toward longer-term strategies, proactive maintenance, non-steroidal options, or systemic treatment evaluation. A month of uninterrupted daily mometasone on large areas in a young child warrants clinician oversight.
Skin thinning on treated areas (shiny, fragile-looking skin), small visible blood vessels where there weren't any before, or bruising more easily at application sites. In a child, unexpected weight gain alongside steroid use and lethargy are signs of systemic absorption worth reporting. These are uncommon with appropriate use but worth knowing.
A common approach: use mometasone daily until the flare clears (typically 7–14 days), then transition to proactive twice-weekly mometasone or step down to twice-weekly fluticasone or low-potency hydrocortisone for maintenance on the same areas. Your clinician will specify the transition, but the principle is: higher potency to clear, lower potency or less frequency to maintain.
Ready to get a personalized treatment plan for your child?
Fern clinicians review every case individually. Most families hear back in under 3 hours.
Start your free assessment →This information is for educational purposes only and is not medical advice. Consult with a healthcare provider before starting any treatment.
“There’s a specific look I recognize in eczema patients who’ve been managing on their own too long. They’ve stopped believing it can get better. Fern shortens that window of suffering. It gets people into real treatment before hopelessness sets in.”